01
Latest News/ Blog
Bringing multi-cancer early detection closer to everyday family medicine
At the Taiwan Association of Family Medicine Annual Meeting 2026, Gene Solutions Taiwan joined family medicine physicians, laboratory professionals, and clinical researchers to discuss the evolving role of multi-cancer early
Gene Solutions Vietnam and Ho Chi Minh City Oncology Hospital Join Forces to Expand the Application of Advanced Genomic Technologies in Cancer Care
Progress in precision oncology does not happen through innovation alone. It is built on scientific evidence, clinical collaboration, and a shared commitment to improving patient outcomes. With this vision
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women’s Genomic Health at ISPD 2026
As a Premier Partner, Gene Solutions presented Asia-led real-world evidence from large-scale NIPT-integrated carrier screening, alongside advances in AI-enabled pregnancy-risk assessment and minimally invasive molecular approaches to women’s health. SINGAPORE,
K-TRACK at ASCO Breakthrough 2026: Two Landmark ctDNA Studies Earn Top 40 Abstracts Honors for Advancing Precision Oncology in Real-world Setting
The ASCO Breakthrough meeting in Singapore convened global oncology leaders to highlight innovations shaping the future of cancer care. In addition to the remarkable real-world data on SPOT-MAS 10 multi-cancer
Gene Solutions’ SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the
Next-generation AI-Powered Multi-Cancer Early Detection Takes Center Stage at Gene Solutions Hong Kong Symposium During MMMC 2026
The conversation around cancer screening is changing. For decades, cancer screening has largely focused on detecting individual cancers through separate tests. With advances in Artificial Intelligence (AI) and multi-omics technologies, new possibilities are emerging for identifying multiple cancers from a single
Introducing SPOT-MAS in Brazil: Advancing Access to Multi-Cancer Screening Through Genomic Innovation in Latin America.
São Paulo, June 25, 2026 — Gene Solutions Brazil and Bioma Genetics announced the introduction of SPOT-MAS in Brazil during an exclusive scientific event held in São Paulo, marking an important step in expanding access to
Gene Solutions Contributes Latest Prenatal Genomics Findings and Women’s Health Research at ISPD 2026
Gene Solutions will join the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD) as a Premier Partner, contributing an Industry Symposium, an Industry Scientific Session, and five selected oral and poster
SPOT-MAS 10 Real-World Data Highlighted by ASCO Ahead of ASCO Breakthrough 2026
Gene Solutions’ SPOT-MAS 10 real-world data was highlighted by ASCO ahead of ASCO Breakthrough 2026, recognizing evidence from 84,145 asymptomatic individuals across 6 Asian countries. Dr. Dang Nguyen also received
ASCO 2026 RECAP | GENE SOLUTIONS PRESENT TWO CLINICAL STUDIES ADVANCING ctDNA APPLICATIONS IN CANCER CARE
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, USA, Gene Solutions, in collaboration with the Medical Genetics Institute (MGI), proudly presented two landmark scientific abstracts.
Best of K‑CONNECT Summit 2026: Translating Multi-omics and AI Into Real-World Precision Oncology
At the K-CONNECT Summit 2026 in Da Nang, more than 250 international experts attended onsite, while over 1,000 participants joined online to explore how multi-omics, liquid biopsy, and Artificial Intelligence
Gene Solutions Malaysia and National Cancer Society Malaysia Join Forces to Expand Access to Multi-Cancer Detection Through Early4Life Initiative
Close to 300 SPOT-MAS 10 tests delivered to communities and frontline institutions, including MINDEF and PDRM Bukit Aman Kuala Lumpur, Malaysia — 15th June 2026 — Gene Solutions Malaysia, in
02
Press release
Gene Solutions Showcases Global Evidence and Responsible Innovation in Prenatal and Women’s Genomic Health at ISPD 2026
Key finding:
SINGAPORE, July 22, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company focused on accessible and responsible genomics, participated as a Premier Partner at the 30th International Conference on Prenatal Diagnosis and Therapy (ISPD 2026), held virtually from July 7–9. Across an industry symposium, a scientific session, two oral presentations and three scientific posters, the company presented data and expert perspectives on how genomics, epigenomics and artificial intelligence may support more comprehensive, personalized and minimally invasive care throughout pregnancy and across women’s health.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions’ SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
Key finding:
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical Oncology. For Gene Solutions, this milestone underscores the growing global relevance of Asia-led multi-cancer detection innovation.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific
Key finding:
DA NANG, Vietnam, June 18, 2026 /PRNewswire/ — Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific.Authors:
GENE SOLUTIONS SGP PTE. LTD.
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions’ SPOT-MAS 10 Multi-Cancer Screening Test
Key finding:
SINGAPORE, May 27, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted Breakthrough Device Designation to SPOT-MAS 10, its multi-omic blood test designed to detect cancer-associated signals.Authors:
GENE SOLUTIONS SGP PTE. LTD.
Gene Solutions Showcases AI-Powered Multi-Omics Liquid Biopsy Innovations at TJCC 2026: Advancing Precision Oncology in Taiwan
Key finding:
TAIPEI, May 22, 2026 /PRNewswire/ — Gene Solutions, an innovative global biotechnology company advancing AI-powered multi-omics solutions for cancer detection and precision oncology, participated in the 30th Taiwan Joint Cancer Conference (TJCC 2026), marking its first major oncology conference presence in Taiwan.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
Authors:
Gene Solutions Genomics Pte Ltd
triSure NIPT Debuts in Taiwan, Expanding Non-Invasive Prenatal Screening Beyond Aneuploidy
Key finding:
TAIPEI, April 14, 2026 /PRNewswire/ — At the prestigious Taiwan Association of Obstetrics and Gynecology (TAOG) 2026 Annual Meeting—the nation’s largest obstetrics and gynecology society established in 1961— Gene Solutions Taiwan officially introduced triSure, a revolutionary non-invasive prenatal screening technology.Authors:
Gene Solutions Genomics Pte Ltd
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
Key finding:
IRVINE, Calif., Jan. 21, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed Tests (LDTs), announced a strategic collaboration to advance U.S. verification and clinical validation of liquid biopsy assays designed for cancer detection, profiling, and monitoring.Authors:
Gene Solutions Genomics Pte Ltd
Gene Solutions Concludes Successful ESMO Asia Congress 2025 with AI-Powered Multi-Omics Liquid Biopsy Symposium and Two Best Poster Awards
Key finding:
SINGAPORE, Dec. 20, 2025 /PRNewswire/ — Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology (ESMO) Asia Congress 2025—held in Singapore on December 5–7. Highlights included a full-house symposium, seven scientific abstracts with two earning Best Poster designations, and meaningful engagement with thousands of oncologists from across the Asia-Pacific region at the company’s exhibition booth.Authors:
Gene Solutions Genomics Pte Ltd
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Key finding:
TAIPEI, Nov. 28, 2025 /PRNewswire/ — Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement with the introduction of SPOT-MAS – an advanced screening solution developed by Gene Solutions, a global leader in precision oncology and genomics, in collaboration with local partner Gene Health.Authors:
Gene Solutions Genomics Pte Ltd
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
Key finding:
HONG KONG, Nov. 17, 2025 /PRNewswire/ — The APAC Precision Oncology Conference 2025, themed Artificial Intelligence (AI) & Multi-omics in Cancer Management, convened in Hong Kong on November 1, marking Lung Cancer Awareness Month with a clear message: AI and multi-omics are no longer theoretical – they are driving real-world advancements in cancer care across the Asia-Pacific (APAC) region.Authors:
Gene Solutions Genomics Pte Ltd
